Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro

European Journal of Endocrinology

Volumn 162, Issue 4, 2010, Pages 771-777

  Muzza, Marina ^a   Cordella, Daniela ^b   Bombled, Johny ^c   Paillerets, Brigitte Bressac De ^c   Guizzardi, Fabiana ^b   Francis, Zelia ^c   Beck Peccoz, Paolo ^a,d   Schlumberger, Martin ^c   Persani, Luca ^a,b   Fugazzola, Laura ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; PROTEIN RET;

ANIMAL CELL; ARTICLE; CASE REPORT; CONTROLLED STUDY; EXON; FEMALE; FOLLOW UP; GENE LOCATION; GENETIC SCREENING; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOMICS; GERM LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PLASMID; PREVALENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RET ONCOGENE; THYROID MEDULLARY CARCINOMA; WESTERN BLOTTING; WILD TYPE;

AGED; AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, MEDULLARY; DNA, NEOPLASM; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NIH 3T3 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RET; SEQUENCE ALIGNMENT; THYROID NEOPLASMS; TRANSFECTION;

EID: 77950314878     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0929     Document Type: Article

References (24)

1. Pachnis V, Mankoo B & Costantini FN. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993 119 1005-1017.
2. Boikos SA & Stratakis CA. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Histology and Histopathology 2008 23 109-116.
3. Eng C & Mulligan LM. Mutations of the RET protooncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors and Hirschsprung disease. Human Mutation 1997 9 97-109.
4. Hansford JR & Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. Journal of Medical Genetics 2000 37 817-827.
5. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F & Pinchera A. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Journal of Clinical Endocrinology and Metabolism 2007 92 4725-4729.
6. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH & Di Fiore PP. Activation of RET as dominant transforming gene by germline mutations in MEN2A and MEN2B. Science 1995 267 381-383.
7. Songyang Z, Carraway KL III, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ & Cantley LC. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995 373 536-539.
8. Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A & Bendlova B. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. Journal of Endocrinological Investigation 2005 28 905-909.
9. Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB & Cerutti JM. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 5438-5443.
10. Fazioli F, Piccinini G, Appolloni G, Bacchiocchi R, Palmonella G, Recchioni R, Pierpaoli E, Silvetti F, Scarpelli M, Bruglia M, Melillo RM, Santoro M, Boscaro M & Taccaliti A. A new germline point mutation in Ret exon 8 (Cys515Ser) in a family with medullary thyroid carcinoma. Thyroid 2008 18 775-782.
11. Bethanis S, Koutsodontis G, Palouka T, Avgoustis C, Yannoukakos D, Bei T, Papadopoulos S, Linos D & Tsagarakis S. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones 2007 6 152-156.
12. Kaldrymides P, Mytakidis N, Anagnostopoulos T, Vassiliou M, Tertipi A, Zahariou M, Rampias T, Koutsodontis G, Konstantopoulou I, Ladopoulou A, Bei T & Yannoukakos D. A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clinical Endocrinology 2006 64 561-566.
13. Peppa M, Boutati E, Pikounis V, Peros G, Kamakari S, Panayiotides I, Economopoulos T, Raptis S & Hadjidakis D. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. European Journal of Endocrinology 2008 159 767-771.
14. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M & Wells SA Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009 19 565-612.
15. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Bocciardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ & Pierotti MA. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995 11 2419-2427.
16. Cordella D, Muzza M, Alberti L, Colombo P, Travaglini P, Beck-Peccoz P, Fugazzola L & Persani L. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma. Endocrine-Related Cancer 2006 13 945-953.
17. Kashuk CS, Stone EA, Grice EA, Portnoy ME, Green ED, Sidow A, Chakravarti A & McCallion AS. Phenotype-genotype correlation in Hirschsprung disease is illuminated by comparative analysis of the RET protein sequence. PNAS 2005 102 8949-8954.
18. Asai N, Iwashita T, Matsuyama M & Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Molecular and Cellular Biology 1995 15 1613-1619.
19. Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, Hodgson S, Clarke S, Pierotti M, Ponder BAJ & Bongarzone I. A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Molecular Endocrinology 2006 20 1633-1643.
20. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H & Takahashi M. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 1999 18 3919-3922.
21. Mise N, Drosten M, Racek T, Tannapfel A & Putzer BM. Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2. Oncogene 2006 25 6637-6647.
22. Ahmed SA, Snow-Bailey K, Highsmith WE, Sun W, Fenwick RG & Mao R. Nine novel germline gene variants in the RET protooncogene identified in twelve unrelated cases. Journal of Molecular Diagnostics 2005 7 283-288.
23. Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J & Ponder BAJ. Germline homozygous mutations at codon 804 in the RET protoncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. Journal of Clinical Endocrinology and Metabolism 2005 90 3454-3457.
24. Fugazzola L, Cerutti N, Mannavola D, Ghilardi G, Alberti L, Romoli R & Beck-Peccoz P. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clinical Endocrinology 2002 56 53-63.